Differential effect of body mass index (BMI) on outcomes of patients treated with docetaxel in prostate cancer: An exploratory analysis.

医学 多西紫杉醇 前列腺癌 四分位间距 内科学 肿瘤科 超重 体质指数 癌症 泌尿科 比例危险模型
作者
Saurav Verma,Ranjit Kumar Sahoo,Prabhjot Singh,Brusabhanu Nayak,K.P. Haresh,Atul Batra
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:39 (6_suppl): 129-129
标识
DOI:10.1200/jco.2021.39.6_suppl.129
摘要

129 Background: Docetaxel is a lipophilic drugs with a high affinity for adipose tissue resulting in a higher volume of distribution.There are contradictory data with regards to the differential effect of docetaxel based on BMI in breast cancer patients. However, there are no such data in patients with prostate cancer. A We performed an exploratory analysis to determine if the benefit of docetaxel in patients with metastatic castration resistant prostate cancer (mCRPC) is modified by BMI. Methods: This is a post hoc analysis of data retrieved from the phase III ENTHUSE M1C study that assessed the efficacy and safety of additional zibotentan in combination with docetaxel in patients with mCRPC (ClinicalTrials.gov identifier: NCT00617669). BMI (kg/m2) was categorized as: 18.5 to < 25, lean; 25 to < 30, overweight; and ≥ 30, obese. Cox regression models were constructed to determine the impact of BMI on progression-free survival (PFS) and overall survival (OS) after adjusting for baseline characteristics. Results: A total of 466 patients were eligible for current analysis, of whom 34%, 46% and 20% were < 65 years, 65-74 years and > 75 years, respectively. The median total and free baseline PSA were 99.5 (interquartile range [IQR], 33.6 to 237.0) ng/mL and 13.9 (IQR, 5.4 to 37.4) ng/mL, respectively. There were 31% (n = 145), 46% (n = 213) and 23% (n = 108) lean, overweight and obese patients. Visceral metastasis was present in 52% patients, while the number of bone metastases were 1-3 in 15%, 4 in 5%, 5-20 in 58% and ≥ 21 in 23%. The median number of cycles of docetaxel administered were 10 (IQR, 6-10). The median PFS was 7.3, 7.7 and 8.4 months (hazard ratio [HR], 0.92; 95% confidence interval [CI], 0.81 to 1.06; P = .26) for lean, overweight and obese patients, respectively. The median OS was 10.3, 10.7 and 12.4 months (HR, 0.75; 95% CI, 0.63 to 0.89; P = .01) for lean, overweight and obese patients, respectively. After adjusting for baseline and tumor related characteristics, there was no association of BMI with PFS (overweight, HR, 0.92; 95% CI, 0.73 to 1.17; P = .50; obese, HR, 0.90; 95% CI, 0.67 to 1.18; P = .42) while overweight (HR, 0.68; 95% CI, 0.52 to 0.91; P = .01) and obese (HR, 0.61; 95% CI, 0.43 to 0.88; P = .01) patients had significantly better OS as compared with lean patients. Conclusions: The differential effect of docetaxel based on BMI was not observed in patients with mCRPC. Interestingly, obese patients had a significantly longer OS, which warrants further investigation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3的应助被XiYang采纳,获得10
刚刚
pfliu完成签到,获得积分10
刚刚
1秒前
传统的无色完成签到,获得积分10
2秒前
SAKURA的应助被绒绒采纳,获得10
2秒前
无极微光的应助被陌路采纳,获得20
2秒前
2秒前
qq完成签到,获得积分10
2秒前
芽芽发布了新的文献求助100
3秒前
3秒前
叶牧尘的应助被樱桃小丸子采纳,获得10
3秒前
木木完成签到,获得积分10
4秒前
5秒前
现实的忆之完成签到 ,获得积分10
6秒前
王姿沣发布了新的文献求助10
6秒前
6秒前
6秒前
8秒前
上官若男的应助被流川枫采纳,获得10
8秒前
Lucas的应助被标致书易采纳,获得10
9秒前
9秒前
plj发布了新的文献求助10
9秒前
lc完成签到,获得积分10
9秒前
上官若男的应助被Lilililili采纳,获得30
10秒前
shiqiyuan发布了新的文献求助20
10秒前
山屿完成签到,获得积分10
11秒前
所所的应助被炙热代丝采纳,获得10
11秒前
丘比特的应助被赖以筠采纳,获得10
11秒前
12秒前
12秒前
义气语兰发布了新的文献求助10
12秒前
是我完成签到,获得积分10
12秒前
13秒前
13秒前
13秒前
13秒前
嵩易凯完成签到,获得积分10
13秒前
许伟洋完成签到,获得积分10
14秒前
LAN完成签到,获得积分10
14秒前
清漪完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175556
求助须知:如何正确求助?哪些是违规求助? 9567240
关于积分的说明 21791502
捐赠科研通 7770174
什么是DOI,文献DOI怎么找? 3431868
关于科研通互助平台的介绍 2556244
邀请新用户注册赠送积分活动 2477299